Clinical Trials Logo

Mother-to-child HIV Transmission clinical trials

View clinical trials related to Mother-to-child HIV Transmission.

Filter by:
  • None
  • Page 1

NCT ID: NCT05017558 Not yet recruiting - Clinical trials for Mother to Child HIV Transmission

Evaluation of Measurement of Maternal Viral Load at Delivery to Optimise Post-natal Prophylaxis of HIV-exposed Newborns

IPOP
Start date: March 2022
Phase:
Study type: Observational

The main objective is to evaluate the operationality of introducing the measurement of viral load in HIV-1 infected mothers at delivery by POC to optimise post-natal prophylaxis and neonatal diagnosis of children according to the estimated risk of MTCT (high risk: HIV viral load (VL) at delivery ≥ 1000 copies/mL, low risk: VL at delivery < 1000 copies/mL) in Conakry, Guinea.

NCT ID: NCT03642704 Completed - Clinical trials for Mother to Child HIV Transmission

HIV Diagnosis and Treatment at Birth for Newborn With High Risk HIV Exposure

DIAVINA
Start date: February 22, 2017
Phase: Phase 4
Study type: Interventional

Principal objective Assess the operational efficacy of a strategy combining early diagnosis and preventive antiretroviral treatment systematically reinforced from the birth* among infants at high risk of infection with HIV** . - in a maximum of 48 hours after delivery - born from HIV infected mothers who received less than 4 weeks of antiretroviral therapy prior delivery and / or HIV infection diagnosed at delivery Intervention, a combined strategy : After positive HIV infection screening from mother in the delivery room and put on antiretroviral treatment of mothers with post partum according to national guidelines , newborns benefit : - Early detection of HIV infection at birth - Without awaiting the outcome of early detection result, a preventive reinforced antiretroviral treatment (zidovudine, lamivudine, nevirapine or zidovudine, lamivudine if their mother is infected with HIV-2), from birth for 12 weeks. - Regular HIV screening until the end of breastfeeding or later to 18 months. - In case of positive results of an HIV test, an antiretroviral treatment with zidovudine, lamivudine, lopinavir, ritonavir whatever serology HIV 1 or 2.

NCT ID: NCT02295800 Completed - Clinical trials for Mother-to-child HIV Transmission

The Kabeho Study: Kigali Antiretroviral and Breastfeeding Assessment for the Elimination of HIV

Start date: April 2013
Phase: N/A
Study type: Observational

The study design includes an observational prospective cohort of HIV-positive pregnant/postpartum women and their infants enrolled during antenatal clinics (or immediately postpartum) from prevention of mother-to-child transmission (PMTCT) programs and followed until the infants reach the age of 18 - 24 months and semi-structure interviews with a sub-set of these women. A second study component involves semi-structured interviews with health care workers (HCW) involved in the PMTCT programs and yearly facility surveys at the selected study facilities.